F-star is a clinical-stage biopharmaceutical company committed to delivering life-changing treatments to cancer patients. Through our highly efficient Modular Antibody Technology platform, we are building and progressing an extensive immuno-oncology pipeline of mAb², a novel class of disruptive bispecific antibodies designed to unlock new biology which cannot be achieved by combining monospecific drugs. F-star's technological expertise and scientific approach have been validated through strategic partnerships with leaders in the pharma and biotech industries.
Find out more at www.f-star.com.